Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor abemaciclib and anti-PD-1 therapy may have a better promise for poorly immune-infiltrated ovarian cancer (119). This evidence concerns the gene CDK4 and ovarian carcinoma.